| Literature DB >> 29369345 |
Lisa K Blum1,2, Richard R L Cao1, Andrew J Sweatt3, Matthew Bill3, Lauren J Lahey1,2, Andrew C Hsi3, Casey S Lee1,2, Sarah Kongpachith1,2, Chia-Hsin Ju1,2, Rong Mao1,2, Heidi H Wong1, Mark R Nicolls2,3, Roham T Zamanian3, William H Robinson1,2.
Abstract
Idiopathic pulmonary arterial hypertension (IPAH) is a devastating pulmonary vascular disease in which autoimmune and inflammatory phenomena are implicated. B cells and autoantibodies have been associated with IPAH and identified as potential therapeutic targets. However, the specific populations of B cells involved and their roles in disease pathogenesis are not clearly defined. We aimed to assess the levels of activated B cells (plasmablasts) in IPAH, and to characterize recombinant antibodies derived from these plasmablasts. Blood plasmablasts are elevated in IPAH, remain elevated over time, and produce IgA autoantibodies. Single-cell sequencing of plasmablasts in IPAH revealed repertoires of affinity-matured antibodies with small clonal expansions, consistent with an ongoing autoimmune response. Recombinant antibodies representative of these clonal lineages bound known autoantigen targets and displayed an unexpectedly high degree of polyreactivity. Representative IPAH plasmablast recombinant antibodies stimulated human umbilical vein endothelial cells to produce cytokines and overexpress the adhesion molecule ICAM-1. Together, our results demonstrate an ongoing adaptive autoimmune response involving IgA plasmablasts that produce anti-endothelial cell autoantibodies in IPAH. These antibodies stimulate endothelial cell production of cytokines and adhesion molecules, which may contribute to disease pathogenesis. These findings suggest a role for mucosally-driven autoimmunity and autoimmune injury in the pathogenesis of IPAH.Entities:
Keywords: Antibodies; Autoimmunity; B cells; Clinical immunology; VDJ recombination
Mesh:
Substances:
Year: 2018 PMID: 29369345 PMCID: PMC5992033 DOI: 10.1002/eji.201747460
Source DB: PubMed Journal: Eur J Immunol ISSN: 0014-2980 Impact factor: 5.532